What is the effect of 10 patients with lung adenocarcinoma taking Osimertinib/Tagressa?

Osimertinib/Tagressa, as a third-generation EGFR tyrosine kinase inhibitor, has become an irreplaceable first-line option in the precision treatment of lung adenocarcinoma. For 10 patients with advanced non-small cell lung adenocarcinoma carrying EGFR-sensitive mutations (such as Exon 19 deletion or L858R mutation), if they all receive standard dose osimertinib (80 mg daily), a more consistent clinical response effect will generally be observed. According to overseas clinical research data such as AURA3 and FLAURA, most patients can experience tumor shrinkage after treatment, and the disease control rate is as high as over 80%. Some patients can experience significant reduction in symptoms such as dyspnea and cough within 3 months.

Among these If stratified according to real-world clinical response differences, about 5-6 patients can achieve partial response (PR), that is, the tumor shrinks by more than 30%; another 2-3 patients can achieve stable disease (SD), that is, there is no significant shrinkage but no progression; the remaining 1-2 patients may develop disease progression (PD) within 3-6 months due to complex mutation types or rapid formation of drug resistance mechanisms. Of particular concern are patients with brain metastases, who have significant central nervous system control effects after using osimertinib. Because the drug has good blood-brain barrier penetration capabilities, it can effectively delay the risk of intracranial recurrence.

However, the differences in efficacy are also closely related to individual patient factors, such as whether they are smokers, whether they are homozygous for gene mutation types, whether there is combined tumor heterogeneity, etc. These factors may affect drug response. In addition, although the resistance problem of osimertinib appeared relatively late, after 9-13 months of use, some patients will still face secondary resistance caused by C797S mutation or MET amplification, thus affecting the overall treatment effect.

Reference materials:https://go.drugbank.com/drugs/DB09330